Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21101485 | 0.77 | ALDH1A1 (0.58) | CYP1A2CYP2C19HTTMEN1KMT2A | |
| SCHEMBL4848136 | 0.75 | TRPV1 (0.61) | MEN1KMT2ATRPV1KDR | |
| SCHEMBL23087526 | 0.74 | KDR (0.60) | CYP1A2HTTMEN1KMT2AHDAC6 | |
| SCHEMBL4198986 | 0.71 | EGFR (0.46) | MEN1KMT2ANPC1KDRRAB9A | |
| SCHEMBL4147660 | 0.71 | HSD17B10 (0.48) | HTTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL28242830 | 0.71 | NPC1 (0.67) | CYP1A2CYP2C19HTTMEN1KMT2A | |
| SCHEMBL24703329 | 0.71 | TRPV1 (0.67) | CYP1A2CYP2C19HTTMEN1KMT2A | |
| SCHEMBL440439 | 0.70 | HTT (1.00) | CYP1A2CYP2C19HTTMEN1KMT2A | |
| SCHEMBL29361503 | 0.70 | HTT (1.00) | CYP1A2CYP2C19HTTMEN1KMT2A | |
| SCHEMBL21282168 | 0.70 | PIK3CA (0.48) | MEN1KMT2AALDH1A1TRPV1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7390907-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-06-24 | — | — | US | disclosed |
| US-7390907-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-06-24 | — | — | US | disclosed |
| US-7390907-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-06-24 | — | — | US | disclosed |
| EP-1780211-A2 | Vanilloid receptor ligands and their use in treatments | Amgen Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1780211-A2 | Vanilloid receptor ligands and their use in treatments | Amgen Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1775295-A1 | Vanilloid receptor ligands and their use in treatments | Amgen Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| EP-1775295-A1 | Vanilloid receptor ligands and their use in treatments | Amgen Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| EP-1670794-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050153984-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-07-14 | — | — | US | disclosed |
| WO-2005033105-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153984-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | CYP1A2 2081/4885CYP2C19 1280/4885HTT 1747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.